Predicting therapeutic responses in head and neck squamous cell carcinoma from < em > TP53 < /em > mutation detected by cell-free DNA

CONCLUSIONS: TP53 mutation could be used as a specific predictor of treatment response in patients with HNSCC. Using cfDNA to detect the TP53 mutations in patients with HSNCC is a feasible method. The results suggested that the therapeutic response in patients could be predicted by detecting TP53 mutations in cfDNA, and large-scale and prospective studies are needed to validate this hypothesis.PMID:38197078 | PMC:PMC10774070 | DOI:10.21037/tcr-23-878
Source: Cell Research - Category: Cytology Authors: Source Type: research